ERCC3 Genotype

Whether you develop certain cancers depends partly on how well your cells fix damaged DNA. ERCC3 (excision repair cross-complementation group 3) is one of the genes that runs that repair machinery, and some inherited versions of it have been tied to a higher chance of ovarian and, more weakly, breast cancer. This test tells you whether you carry one of those variants.

Because this is a genetic test, the answer is fixed for life and only needs to be found once. Its value is not in a number you track, but in a piece of inherited information that can reshape how closely you and your relatives watch for specific cancers.

What This Gene Actually Does

ERCC3 carries the blueprint for a protein called XPB, a molecular motor that helps open up the DNA double helix. XPB is part of a larger machine (called TFIIH) that does two jobs: it helps your cells read their genes to make proteins, and it opens up DNA around damage so a repair crew can cut out the bad section.

That repair process, known as nucleotide excision repair, is your main defense against the kind of DNA damage caused by sunlight and some chemicals in tobacco smoke. When both copies of ERCC3 are badly broken, this defense fails. When only one copy carries a damaging change, repair capacity is partly reduced, which is where the more subtle cancer risk comes in.

A Rare but Severe Repair Disease

The clearest consequence of ERCC3 damage is a group of rare inherited disorders that appear when a person inherits a damaging variant in both copies of the gene. The best known is xeroderma pigmentosum (a condition of extreme sensitivity to sunlight and a high risk of skin cancer), sometimes overlapping with Cockayne syndrome, which adds developmental and neurological problems. A third disorder, trichothiodystrophy (marked by brittle hair, scaly skin, and developmental delays), has also been linked to ERCC3 variants.

Severity tracks with the type of variant. People with a partly working single-letter change tend to have milder disease, while those carrying variants that cut the protein short on both copies have the severe form. These conditions are extraordinarily rare: by 2020, only about nine disease-causing ERCC3 variants had been reported, across roughly a dozen affected people from eight unrelated families, which shows how uncommon they are.

Ovarian Cancer Risk

The strongest cancer signal for carrying a single damaged copy of ERCC3 is for ovarian cancer. In a study of 1,311 people tested for hereditary breast and ovarian cancer, variants that shorten the ERCC3 protein turned up in 0.99%, compared with about 0.22% to 0.24% of people without cancer.

Carriers had roughly 4.7 times the odds of ovarian cancer (odds ratio 4.74). That sounds dramatic, but the confidence range was very wide (1 to 14.34), meaning the true effect could be anywhere from barely raised to very large. This is an emerging association, not a settled one.

What this means for you: if you carry a damaging ERCC3 variant and have a family history of ovarian cancer, it is a reason to discuss earlier or more intensive ovarian surveillance with a specialist, not a reason to assume ovarian cancer is inevitable.

Breast Cancer Risk

A recurrent ERCC3 variant that shortens the protein was first tied to familial breast cancer in families of Ashkenazi Jewish ancestry. In the larger hereditary cancer study, though, the breast cancer link was weaker and did not reach statistical significance (about 2.3 times the odds, odds ratio 2.25, with a confidence range of 0.6 to 5.93 that crosses no effect).

So the honest read is that ERCC3 may contribute to breast cancer risk, especially in specific ancestries, but the current evidence is much softer than for ovarian cancer.

Prostate and Bladder Cancer Signals

In pooled high-risk prostate cancer families, a rare single-letter change in the protein (rs145201970, also called p.R283C) was significantly linked to prostate cancer (a probability of about 0.0003 that the finding was chance) and is predicted to disrupt part of the protein's structure. In advanced bladder and other urinary tract cancers, damaging ERCC3 variants were found in 4 of 586 patients, about 0.7%, though that study did not calculate a specific risk figure for ERCC3.

For several other cancers, the story is mostly negative. Individual ERCC3 variants showed no clear link to lung cancer on their own, head and neck cancer, melanoma survival, or endometrial cancer, even when the gene was part of larger repair-gene panels.

Sources: Stradella et al. 2020 (ovarian and breast); Foley et al. 2024 (prostate); Carlo et al. 2020 (urinary tract).

When Broken Repair Does Not Mean Cancer

There is an apparent contradiction worth resolving. Some patients with severe ERCC3 repair defects had surprisingly mild skin symptoms and no skin tumors even past age 40, despite their cells being poor at fixing DNA. This tells you that losing repair capacity is not a simple on-off switch for cancer.

ERCC3 is best thought of as a risk modifier whose effect depends on which exact variant you carry, whether one or both copies are affected, your ancestry, and your exposures such as sunlight. Two people with an abnormal ERCC3 result can face very different risks, which is exactly why the specific variant matters more than the yes-or-no fact of carrying one.

A Result You Learn Once and Keep

Your ERCC3 genotype is written into your DNA and does not change, so this is a one-time test. There is no trend to track and no reason to repeat it, unless a lab needs to confirm an unexpected variant using a second method.

The value comes from acting on the result over years, not from retesting. If you carry a damaging variant, the follow-up is about the cancers the gene is linked to. That means the testing you actually track over time is cancer screening appropriate to your sex and family history, not another ERCC3 test.

What to Do With an Unexpected Result

A damaging ERCC3 result is a starting point for a workup, not a diagnosis. The first step is confirming exactly which variant you carry and how it is classified, because a variant labeled as uncertain is not the same as a clearly harmful one and should not drive drastic action.

• Confirm the variant: ask whether a protein-shortening (truncating) change, a milder single-letter change, or a variant of uncertain meaning was found, since these carry very different weight.
• Bring in a specialist: a genetic counselor or clinical geneticist can place the result in the context of your personal and family history.
• Match surveillance to the risk: for a protein-shortening variant with relevant family history, discuss earlier or closer ovarian and breast cancer screening.
• Tell your relatives: because this is inherited, first-degree family members each have a meaningful chance of carrying the same variant.

When a Genetic Result Can Mislead You

Genetic tests fail differently from blood tests. The most common trap is coverage: this assay only looks for the specific variants it is designed to detect, so a negative result does not rule out every possible ERCC3 change or variants in other repair genes.

• Panel coverage: a normal ERCC3 result means the tested positions were normal, not that the whole gene was read end to end.
• Ancestry effects: some ERCC3 variants are common in one population (such as the recurrent Ashkenazi Jewish variant) and rare in others, so the meaning of a result depends on your background.
• Uncertain variants: an unexpected change may be reported as of uncertain significance, which is not evidence of disease and can cause needless worry.
• Sample source: standard testing assumes inherited DNA from normal tissue, so contamination from a tumor sample can occasionally produce a misleading call.